Company intelligence / Profile preview

Puyi Biotechnology

Shanghai, Shanghai, Chinaen.puyibio.com ↗
Ownership
Private
Development stage
Other
01

Overview

Puyi Biotechnology’s lead products, including Corina Intrauterine Drug-Eluting System (approved 2024 in China) and BISORB Drug-Eluting Sinus Absorbable System (nationally registered in China, registered in Indonesia 2024), have both shown statistically significant and clinically meaningful efficacy in randomized, controlled trials, advancing new standards of care in intrauterine adhesion and chronic rhinosinusitis.

Therapeutic areas
Women's HealthPulmonology
Modalities
DeviceDrug-device combinationSmall molecule
Industry
Biotech
02

Drug pipeline

1 asset

Xiangtong

Unknown

Beyond the preview

Go deeper on Puyi Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Puyi Biotechnology.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call